CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 136 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 12.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $592 | -100.0% | 344,169 | +38.1% | 0.06% | -54.3% |
| Q3 2021 | $1,268,000 | +756.8% | 249,146 | +1204.9% | 0.13% | +416.0% |
| Q1 2021 | $148,000 | -29.2% | 19,093 | -40.1% | 0.02% | -26.5% |
| Q4 2020 | $209,000 | +11.2% | 31,854 | +12.8% | 0.03% | +9.7% |
| Q3 2020 | $188,000 | -44.5% | 28,251 | -30.6% | 0.03% | -83.6% |
| Q2 2020 | $339,000 | -28.0% | 40,735 | -33.7% | 0.19% | +60.2% |
| Q1 2020 | $471,000 | -51.3% | 61,416 | -47.3% | 0.12% | +4.4% |
| Q4 2019 | $968,000 | +68.1% | 116,516 | +49.4% | 0.11% | +44.9% |
| Q3 2019 | $576,000 | -21.8% | 77,997 | +18.7% | 0.08% | -6.0% |
| Q2 2019 | $737,000 | +92.4% | 65,695 | +84.2% | 0.08% | +112.8% |
| Q1 2019 | $383,000 | -26.9% | 35,658 | +2.8% | 0.04% | -35.0% |
| Q4 2018 | $524,000 | -18.9% | 34,700 | -0.6% | 0.06% | +66.7% |
| Q3 2018 | $646,000 | -43.5% | 34,900 | -30.2% | 0.04% | -36.8% |
| Q2 2018 | $1,143,000 | +355.4% | 50,000 | +466.1% | 0.06% | +338.5% |
| Q1 2018 | $251,000 | – | 8,833 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,803,700 | $25,130,000 | 0.91% |
| Altium Capital Management LP | 663,800 | $2,874,000 | 0.79% |
| Rubric Capital Management LP | 2,406,449 | $10,420,000 | 0.49% |
| RTW INVESTMENTS, LP | 6,029,700 | $26,109,000 | 0.38% |
| Orbimed Advisors | 3,214,509 | $13,919,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 152,345 | $660,000 | 0.13% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 980,085 | $4,244,000 | 0.12% |
| Point72 Asset Management, L.P. | 6,303,025 | $27,292,000 | 0.11% |
| Sender Co & Partners, Inc. | 40,720 | $176,000 | 0.09% |
| Manteio Capital LLC | 15,067 | $65,000 | 0.08% |